Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

SMTI US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

SMTI US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Sanara MedTech Inc.(SMTI US)

$32.35-0.190.58%Ext:$32.38+0.030.09%(Market Closed · 01:00:02 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

Sanara MedTech Inc.(SMTI US)

$32.35-0.190.58%Ext:$32.38+0.030.09%(Market Closed · 01:00:02 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
Ask AI
Ask AI

Sanara MedTech Inc. — Company Profile

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Seth D. Yon
Headquarters
Fort Worth, TX, US
IPO Date
Apr 7, 1994
Employees
108
Website
sanaramedtech.com

Key Metrics

Price
$34.85
Market Cap
$320.38M
Revenue (TTM)
$27.80M
Net Income (TTM)
$458.96K
EPS (TTM)
0.05
P/E (TTM)
-9.54
P/B (TTM)
45.58
Dividend Yield
0.00%
ROE (TTM)
6.53%
ROA (TTM)
0.66%

Sanara MedTech Inc. — Company Profile

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Seth D. Yon
Headquarters
Fort Worth, TX, US
IPO Date
Apr 7, 1994
Employees
108
Website
sanaramedtech.com

Key Metrics

Price
$34.85
Market Cap
$320.38M
Revenue (TTM)
$27.80M
Net Income (TTM)
$458.96K
EPS (TTM)
0.05
P/E (TTM)
-9.54
P/B (TTM)
45.58
Dividend Yield
0.00%
ROE (TTM)
6.53%
ROA (TTM)
0.66%
Operating Margin
9.52%
Beta
0.57

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

Website
sanaramedtech.com
Location
Fort Worth, TX, US
Phone817 529 2300
Employees108
CEOSeth D. Yon
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateApr 7, 1994

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • Sanara MedTech Inc. (SMTI) Surpasses Q3 Earnings Estimates12 Nov
  • Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)12 Nov
  • 15,945 Shares of Sanara MedTech Inc. $SMTI Bought by Bank of America Corp DE5 Oct
  • Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?11 Sep
  • Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?11 Sep
  • Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI10 Sep
  • SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders29 Aug
  • SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders29 Aug

Key Stats

Trading

Px/Chg 1D$34.85 / -0.09%
Avg Volume58.38K
Beta0.57
Mkt Cap320.38M
FD Mkt Cap317.90M

Float

Shrs Out/Float9.19M / 3.18M
Short Float0.11%
Days to Cover4.59
Stock Repurchased$0.00

Current Valuation

EV355.14M
EV/EBITDA41.66
EV/Sales3.30
P/B45.58
P/S2.98
FCF Yield-0.78%
ROE6.53%
ROA0.66%
Current Ratio2.28

Estimates

P/E-9.54
Est P/E0.00
Est EPS-0.04
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings93.88-40.89-60.45-30.81-96.52698.06
Price / Sales6.347.084.003.445.6411.53
Price / Book Value18.587.765.807.5626.2045.58
Price / Free Cash Flow-277.94-51.50-74.09-1,176.6740.23-127.68
ENTERPRISE VALUE METRICS
Enterprise Value287.7316.3266.5313.7187.0355.1
Enterprise Value / Sales6.846.904.103.626.7912.78
Enterprise Value / EBITDA-171.25-27.35-921.92-168.64134.13127.55
Enterprise Value / EBIT56.63-22.70-67.23-46.25257.66161.65

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue43.8%24.145.865.086.7103.1
Gross Income43.6%21.839.557.178.592.9
EBITDA—-7.2-11.6-0.3-1.99.0
EBIT—-8.0-13.9-4.0-6.86.4
Net Income47.6%-7.9-7.9-4.3-9.7-37.6
EPS (Diluted)41.7%-1.08-1.00-0.52-1.14-4.36
BALANCE SHEET
Cash & ST Inv-2.9%18.79.05.115.916.6
Total Assets19%36.461.073.988.172.9
Total Liabilities81%6.219.329.349.267.0
Total Shareholder Equity-33.7%30.641.844.839.45.9
CASH FLOW
Net Operating Cash Flow—-4.8-5.6-3.2-0.06.8
Cap Ex57.6%-0.8-0.7-0.3-0.2-4.6
Free Cash Flow—-5.6-6.3-3.5-0.32.2

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)32.77
Basic Shares9.19
Market Cap301.3
Diluted Shares8.66
Fully Diluted Shares Outstanding8.66
Fully Diluted Market Cap283.9
+Consolidated Debt48.5
−In-the-Money Convertible Debt—
+Capital Leases2.1
+Operating Leases—
−Cash & Equivalents-15.4
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-0.0
+Pension Liabilities—
Enterprise Value334.4

Segment data

Revenue

by Products and services

  • Royalty100%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN

Operating Margin
9.52%
Beta
0.57

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.

Website
sanaramedtech.com
Location
Fort Worth, TX, US
Phone817 529 2300
Employees108
CEOSeth D. Yon
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateApr 7, 1994

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • Sanara MedTech Inc. (SMTI) Surpasses Q3 Earnings Estimates12 Nov
  • Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)12 Nov
  • 15,945 Shares of Sanara MedTech Inc. $SMTI Bought by Bank of America Corp DE5 Oct
  • Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?11 Sep
  • Are SMTI, LAB, ATKR, VAL Obtaining Fair Deals for their Shareholders?11 Sep
  • Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI10 Sep
  • SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders29 Aug
  • SMTI Stock Alert: Halper Sadeh LLC is Investigating Whether Sanara MedTech Inc. is Obtaining a Fair Price for its Shareholders29 Aug

Key Stats

Trading

Px/Chg 1D$34.85 / -0.09%
Avg Volume58.38K
Beta0.57
Mkt Cap320.38M
FD Mkt Cap317.90M

Float

Shrs Out/Float9.19M / 3.18M
Short Float0.11%
Days to Cover4.59
Stock Repurchased$0.00

Current Valuation

EV355.14M
EV/EBITDA41.66
EV/Sales3.30
P/B45.58
P/S2.98
FCF Yield-0.78%
ROE6.53%
ROA0.66%
Current Ratio2.28

Estimates

P/E-9.54
Est P/E0.00
Est EPS-0.04
Est PEG0.00

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings93.88-40.89-60.45-30.81-96.52698.06
Price / Sales6.347.084.003.445.6411.53
Price / Book Value18.587.765.807.5626.2045.58
Price / Free Cash Flow-277.94-51.50-74.09-1,176.6740.23-127.68
ENTERPRISE VALUE METRICS
Enterprise Value287.7316.3266.5313.7187.0355.1
Enterprise Value / Sales6.846.904.103.626.7912.78
Enterprise Value / EBITDA-171.25-27.35-921.92-168.64134.13127.55
Enterprise Value / EBIT56.63-22.70-67.23-46.25257.66161.65

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue43.8%24.145.865.086.7103.1
Gross Income43.6%21.839.557.178.592.9
EBITDA—-7.2-11.6-0.3-1.99.0
EBIT—-8.0-13.9-4.0-6.86.4
Net Income47.6%-7.9-7.9-4.3-9.7-37.6
EPS (Diluted)41.7%-1.08-1.00-0.52-1.14-4.36
BALANCE SHEET
Cash & ST Inv-2.9%18.79.05.115.916.6
Total Assets19%36.461.073.988.172.9
Total Liabilities81%6.219.329.349.267.0
Total Shareholder Equity-33.7%30.641.844.839.45.9
CASH FLOW
Net Operating Cash Flow—-4.8-5.6-3.2-0.06.8
Cap Ex57.6%-0.8-0.7-0.3-0.2-4.6
Free Cash Flow—-5.6-6.3-3.5-0.32.2

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)32.77
Basic Shares9.19
Market Cap301.3
Diluted Shares8.66
Fully Diluted Shares Outstanding8.66
Fully Diluted Market Cap283.9
+Consolidated Debt48.5
−In-the-Money Convertible Debt—
+Capital Leases2.1
+Operating Leases—
−Cash & Equivalents-15.4
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-0.0
+Pension Liabilities—
Enterprise Value334.4

Segment data

Revenue

by Products and services

  • Royalty100%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN